Disruption of nNOS–NOS1AP protein–protein interactions suppresses neuropathic pain in mice
- 9 January 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
- Vol. 159 (5) , 849-863
Abstract
Elevated N-methyl-d-aspartate receptor (NMDAR) activity is linked to central sensitization and chronic pain. However, NMDAR antagonists display limited therapeutic potential because of their adverse side effects. Novel approaches targeting the NR2B-PSD95-nNOS complex to disrupt signaling pathways downstream of NMDARs show efficacy in preclinical pain models. Here, we evaluated the involvement of interactions between neuronal nitric oxide synthase (nNOS) and the nitric oxide synthase 1 adaptor protein (NOS1AP) in pronociceptive signaling and neuropathic pain. TAT-GESV, a peptide inhibitor of the nNOS–NOS1AP complex, disrupted the in vitro binding between nNOS and its downstream protein partner NOS1AP but not its upstream protein partner postsynaptic density 95 kDa (PSD95). Putative inactive peptides (TAT-cp4GESV and TAT-GESVΔ1) failed to do so. Only the active peptide protected primary cortical neurons from glutamate/glycine-induced excitotoxicity. TAT-GESV, administered intrathecally (i.t.), suppressed mechanical and cold allodynia induced by either the chemotherapeutic agent paclitaxel or a traumatic nerve injury induced by partial sciatic nerve ligation. TAT-GESV also blocked the paclitaxel-induced phosphorylation at Ser15 of p53, a substrate of p38 MAPK. Finally, TAT-GESV (i.t.) did not induce NMDAR-mediated motor ataxia in the rotarod test and did not alter basal nociceptive thresholds in the radiant heat tail-flick test. These observations support the hypothesis that antiallodynic efficacy of an nNOS–NOS1AP disruptor may result, at least in part, from blockade of p38 MAPK-mediated downstream effects. Our studies demonstrate, for the first time, that disrupting nNOS–NOS1AP protein–protein interactions attenuates mechanistically distinct forms of neuropathic pain without unwanted motor ataxic effects of NMDAR antagonists.Keywords
This publication has 58 references indexed in Scilit:
- CCL-1 in the spinal cord contributes to neuropathic pain induced by nerve injuryCell Death & Disease, 2013
- Evidence That Spinal Astrocytes but Not Microglia Contribute to the Pathogenesis of Paclitaxel-Induced Painful NeuropathyThe Journal of Pain, 2012
- Perturbing PSD-95 Interactions With NR2B-subtype Receptors Attenuates Spinal Nociceptive Plasticity and Neuropathic PainMolecular Therapy, 2011
- The response of spinal microglia to chemotherapy-evoked painful peripheral neuropathies is distinct from that evoked by traumatic nerve injuriesNeuroscience, 2011
- Disruption of nNOS‐PSD95 protein–protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodentsBritish Journal of Pharmacology, 2009
- MAP kinase and painBrain Research Reviews, 2009
- Activation of p38 MAP kinase is involved in central neuropathic pain following spinal cord injuryExperimental Neurology, 2008
- Pharmacological Switch in Aβ-Fiber Stimulation-Induced Spinal Transmission in Mice with Partial Sciatic Nerve InjuryMolecular Pain, 2008
- Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkineBrain, Behavior, and Immunity, 2007
- p38 MAPK, Microglial Signaling, and Neuropathic PainMolecular Pain, 2007